

 Early Warning System

EIB-20230988

LEYDEN LABS (IEU TI HERA)



## Quick Facts

Countries	Netherlands
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-12-23
Borrower	Leyden Laboratories B.V.
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 20.81 million
Project Cost (USD)	\$ 74.91 million



---

## Project Description

According to the Bank's website, the project supports the RDI activities by a biotech company to further develop antibodies to be administered intranasally, directly to the nasal mucosa, providing protection against respiratory viral infections, namely influenza A & B and coronaviruses.

The project's objectives are the development of the promoter's mucosal immunity platform and of its prophylactic nasal sprays against respiratory viruses such as influenza and coronaviruses to generate pre-clinical and clinical data.



---

### Early Warning System Project Analysis

According to the Environmental and Social Data Sheet, the Promoter has effective policies and operating procedures in place, which are in line with industry standards. The project concerns investments in research and development for which no significant impact on the environment is expected.



---

## Investment Description

- European Investment Bank (EIB)



---

## Private Actors Description

*Leyden Laboratories B.V.*, founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses, by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital / Brook Byers and Bluebird Ventures.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Leyden Laboratories B.V.	Client	-



---

## Contact Information

Contact: Tim Smit

Email: [t.smit@eib.org](mailto:t.smit@eib.org)

Phone: + 352 4379 - 89076

## ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

## ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: [complaints@eib.org](mailto:complaints@eib.org), by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: [http://www.eib.org/attachments/strategies/complaints\\_mechanism\\_policy\\_en.pdf](http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf)

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>





---

## Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - LEYDEN LABS \(IEU TI HERA\)](#)

## Media

- [The Netherlands: Leyden Labs lands €20 million EIB investment facilitated by HERA to advance pandemi](#)



---

### Other Related Projects

- EIB-20230791 THEMATIC INNOVATION (INVESTEU VD) LE II